{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:53:36Z","timestamp":1769068416551,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Research Centers In Minority Institutions (RCMI) -  Florida Agricultural and Mechanical University, Tallahassee, Florida, 32307"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40121-020-00378-3","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T17:22:40Z","timestamp":1612286560000},"page":"149-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4246-022X","authenticated-orcid":false,"given":"Nathaniel","family":"Eraikhuemen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Julien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alandra","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dovena","family":"Lazaridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"378_CR1","unstructured":"American Thoracic Society\u2014Patient Resources. https:\/\/www.thoracic.org\/patients\/patient-resources\/. Accessed Jan 31, 2020."},{"key":"378_CR2","unstructured":"Sattar SBA, Sharma S. Bacterial pneumonia. StatPearls, Treasure Island. 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513321\/. Accessed Dec 18 2019."},{"key":"378_CR3","unstructured":"Agency for Healthcare Research and Quality. Community-acquired pneumonia in the emergency department setting. AHRQ. 2018. http:\/\/www.ahrq.gov\/sites\/default\/files\/wysiwyg\/professionals\/quality-patient-safety\/quality-resources\/tools\/cap-toolkit\/cap_ed-pamphlet.pdf.  Accessed June 15, 2020."},{"key":"378_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1493","author":"J Ramirez","year":"2017","unstructured":"Ramirez J. Adults hospitalized with pneumonia in the United States: incidence epidemiology and mortality. Open Forum Infect Dis. 2017. https:\/\/doi.org\/10.1093\/ofid\/ofx163.1493.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"378_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3810\/pgm.2010.03.2130","volume":"122","author":"TM File","year":"2010","unstructured":"File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130\u201341. https:\/\/doi.org\/10.3810\/pgm.2010.03.2130.","journal-title":"Postgrad Med"},{"issue":"1","key":"378_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12877-018-0787-2","volume":"18","author":"JD Brown","year":"2018","unstructured":"Brown JD, Harnett J, Chambers R, Sato R. The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. BMC Geriatr. 2018;18(1):92. https:\/\/doi.org\/10.1186\/s12877-018-0787-2.","journal-title":"BMC Geriatr"},{"issue":"49","key":"378_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3238\/arztebl.2017.0838","volume":"114","author":"M Kolditz","year":"2017","unstructured":"Kolditz M, Ewig S. Community-acquired pneumonia in adults. Dtsch Arztebl Int. 2017;114(49):838\u201348. https:\/\/doi.org\/10.3238\/arztebl.2017.0838.","journal-title":"Dtsch Arztebl Int"},{"key":"378_CR8","unstructured":"Centers for Disease Control and Prevention. Pneumococcal disease | Transmission and those at high risk. CDC. https:\/\/www.cdc.gov\/pneumococcal\/about\/risk-transmission.html. Accessed Jan 28, 2020."},{"issue":"11","key":"378_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","volume":"68","author":"A Torres","year":"2013","unstructured":"Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057\u201365. https:\/\/doi.org\/10.1136\/thoraxjnl-2013-204282.","journal-title":"Thorax"},{"key":"378_CR10","unstructured":"American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;17:388\u2013416."},{"key":"378_CR11","unstructured":"Regunath H, Oba Y. Community-acquired pneumonia. StatPearls, Treasure Island. 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430749\/. Accessed Jan 5, 2020."},{"issue":"6","key":"378_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.7861\/clinmedicine.12-6-538","volume":"12","author":"JS Brown","year":"2012","unstructured":"Brown JS. Community-acquired pneumonia. Clin Med (Lond). 2012;12(6):538\u201343. https:\/\/doi.org\/10.7861\/clinmedicine.12-6-538.","journal-title":"Clin Med (Lond)"},{"issue":"7","key":"378_CR13","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581st","volume":"200","author":"J Metlay","year":"2019","unstructured":"Metlay J, Waterer G, Long A, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367. https:\/\/doi.org\/10.1164\/rccm.201908-1581st.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"378_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4103\/lungindia.lungindia_38_19","volume":"36","author":"J Ahdal","year":"2019","unstructured":"Ahdal J, Nayar S, Hasan A, Waghray P, Ramananthan S, Jain R. Management of community-acquired bacterial pneumonia in adults: limitations of current antibiotics and future therapies. Lung India. 2019;36(6):525. https:\/\/doi.org\/10.4103\/lungindia.lungindia_38_19.","journal-title":"Lung India"},{"issue":"4","key":"378_CR15","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jaci.2015.10.026","volume":"137","author":"MN Jeffres","year":"2016","unstructured":"Jeffres MN, Narayanan PP, Shuster JE, Schramm GE. Consequences of avoiding \u03b2-lactams in patients with \u03b2-lactam allergies. J Allergy Clin Immunol. 2016;137(4):1148\u201353. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.026.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"378_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/aln.0000000000002252","volume":"129","author":"J Hermanides","year":"2018","unstructured":"Hermanides J, Lemkes BA, Prins JM, Hollmann MW, Terreehorst I. Presumed \u03b2-lactam allergy and cross-reactivity in the operating theater. Anesthesiology. 2018;129(2):335\u201342. https:\/\/doi.org\/10.1097\/aln.0000000000002252.","journal-title":"Anesthesiology"},{"issue":"3","key":"378_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/pharmacy7030135","volume":"7","author":"KM Shaeer","year":"2019","unstructured":"Shaeer KM, Chahine EB, Varghese Gupta S, Cho JC. Macrolide allergic reactions. Pharmacy (Basel). 2019;7(3):135. https:\/\/doi.org\/10.3390\/pharmacy7030135.","journal-title":"Pharmacy (Basel)"},{"key":"378_CR18","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2016. http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu16.pdf. Accessed Jun 22, 2020."},{"key":"378_CR19","unstructured":"XENLETA\u2122 (lefamulin) [package insert]. King of Prussia, PA: Nabriva Therapeutics; 2019."},{"issue":"9","key":"378_CR20","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1164\/ajrccm.164.9.2108099b","volume":"164","author":"C Brun-Buisson","year":"2001","unstructured":"Brun-Buisson C, Lemaire F. Administration of antibiotics for pneumonia during respiratory failure: reaching the target. Am J Respir Crit Care Med. 2001;164(9):1554\u20135. https:\/\/doi.org\/10.1164\/ajrccm.164.9.2108099b.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"378_CR21","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1128\/aac.00712-11","volume":"55","author":"TP Lodise","year":"2011","unstructured":"Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother. 2011;55(12):5507\u201311. https:\/\/doi.org\/10.1128\/aac.00712-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supplement_3","key":"378_CR22","doi-asserted-by":"publisher","first-page":"iii11","DOI":"10.1093\/jac\/dkz086","volume":"74","author":"WW Wicha","year":"2019","unstructured":"Wicha WW, Strickmann DB, Paukner S. Pharmacokinetics\/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrobial Chemother. 2019;74(Supplement_3):iii11\u2013iii18. https:\/\/doi.org\/10.1093\/jac\/dkz086.","journal-title":"J Antimicrobial Chemother"},{"key":"378_CR23","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. FDA. 2018. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability. Accessed July 2, 2020"},{"key":"378_CR24","unstructured":"Center for Drug Evaluation and Research. Serious low blood sugar, new mental health effects with fluoroquinolones. US Food and Drug Administration. 2018. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side. Accessed July 2, 2020."},{"key":"378_CR25","unstructured":"Center for Drug Evaluation and Research. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. US Food and Drug Administration. 2018. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics. Accessed June 27, 2020."},{"key":"378_CR26","unstructured":"Nabriva Therapeutics. Nabriva Therapeutics receives U.S. FDA approval of Xenleta\u2122 (lefamulin) to treat community-acquired bacterial pneumonia (CABP). 2019. Available at: https:\/\/investors.nabriva.com\/news-releases\/news-release-details\/nabriva-therapeutics-receives-us-fda-approval-xenleta. Accessed July 03, 2020."},{"issue":"Supplement_3","key":"378_CR27","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/jac\/dkz084","volume":"74","author":"KA Rodvold","year":"2019","unstructured":"Rodvold KA. Introduction: lefamulin and pharmacokinetic\/pharmacodynamic rationale to support the dose selection of lefamulin. J Antimicrob Chemother. 2019;74(Supplement_3):iii2\u2013iii4. https:\/\/doi.org\/10.1093\/jac\/dkz084.","journal-title":"J Antimicrob Chemother"},{"key":"378_CR28","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1093\/jac\/dku123","volume":"69","author":"E van Duijkeren","year":"2014","unstructured":"van Duijkeren E, Greko C, Pringle M, et al. Pleuromutilins: use in food-producing animals in the European Union, development of resistance and impact on human and animal health. J Antimicrob Chemother. 2014;69:2022\u201331.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"378_CR29","doi-asserted-by":"publisher","first-page":"a027110","DOI":"10.1101\/cshperspect.a027110","volume":"7","author":"S Paukner","year":"2017","unstructured":"Paukner S, Riedl R. Pleuromutilins: potent drugs for resistant bugs\u2014mode of action and resistance. Cold Spring Harb Perspect Med. 2017;7(1):a027110. https:\/\/doi.org\/10.1101\/cshperspect.a027110.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"378_CR30","doi-asserted-by":"publisher","first-page":"39004","DOI":"10.1038\/srep39004","volume":"6","author":"Z Eyal","year":"2016","unstructured":"Eyal Z, Matzov D, Krupkin M, et al. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep. 2016;6(1):39004. https:\/\/doi.org\/10.1038\/srep39004.","journal-title":"Sci Rep"},{"issue":"9","key":"378_CR31","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/phar.2166","volume":"38","author":"MP Veve","year":"2018","unstructured":"Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018;38(9):935\u201346. https:\/\/doi.org\/10.1002\/phar.2166.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"378_CR32","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/cid\/ciz090","volume":"69","author":"TM File Jr","year":"2019","unstructured":"File TM Jr, Goldberg L, Das A, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP\u00a01) trial. Clin Infect Dis. 2019;69(11):1856\u201367. https:\/\/doi.org\/10.1093\/cid\/ciz090.","journal-title":"Clin Infect Dis"},{"issue":"Supplement_3","key":"378_CR33","doi-asserted-by":"publisher","first-page":"iii19","DOI":"10.1093\/jac\/dkz087","volume":"74","author":"WW Wicha","year":"2019","unstructured":"Wicha WW, Prince WT, Lell C, Heilmayer W, Gelone SP. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. J Antimicrob Chemother. 2019;74(Supplement_3):iii19\u201326. https:\/\/doi.org\/10.1093\/jac\/dkz087.","journal-title":"J Antimicrob Chemother"},{"key":"378_CR34","unstructured":"Wicha W, Lell C, Seltzer E, Prince WT, Gelone S. Pharmacokinetics and safety of an oral, immediate-release (IR) tablet formulation of lefamulin in fed and fasted healthy subjects. Poster presented at 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna; 2017."},{"key":"378_CR35","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.18203\/2319-2003.ijbcp20195297","volume":"8","author":"A Dubey","year":"2019","unstructured":"Dubey A, Maggo S, Karan A, Singh N, Bhaskaran S. Lefamulin: novel pleuromutilin drug for community acquired bacterial pneumonia. Int J Basic Clin Pharmacol. 2019;8:2783. https:\/\/doi.org\/10.18203\/2319-2003.ijbcp20195297.","journal-title":"Int J Basic Clin Pharmacol"},{"key":"378_CR36","unstructured":"Wicha WW, Ivezic-Schoenfeld Z, Novak R. Pre-clinical efficacy of BC-3781 in thigh and bacteremia infections caused by staphylococci. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract F1-2109; 2010."},{"key":"378_CR37","doi-asserted-by":"publisher","first-page":"III35","DOI":"10.1093\/jac\/dkz089","volume":"74","author":"SM Bhavnani","year":"2019","unstructured":"Bhavnani SM, Zhang L, Hammel JP, et al. Pharmacokinetic\/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia. J Antimicrob Chemother. 2019;74:III35\u201341. https:\/\/doi.org\/10.1093\/jac\/dkz089.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"378_CR38","doi-asserted-by":"publisher","first-page":"e02161","DOI":"10.1128\/AAC.02161-18","volume":"63","author":"S Paukner","year":"2019","unstructured":"Paukner S, Gelone SP, Arends SJR, Flamm RK, Sader HS. Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015\u20132016). Antimicrob Agents Chemother. 2019;63(4):e02161-e2218. https:\/\/doi.org\/10.1128\/AAC.02161-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"378_CR39","volume-title":"Laboratory diagnosis of mycoplasmal infections","author":"KB Waites","year":"2001","unstructured":"Waites KB, Nolte FS. Laboratory diagnosis of mycoplasmal infections. Washington: ASM; 2001."},{"issue":"2","key":"378_CR40","doi-asserted-by":"publisher","first-page":"e02008","DOI":"10.1128\/AAC.02008-16","volume":"61","author":"KB Waites","year":"2017","unstructured":"Waites KB, Crabb DM, Duffy LB, Jensen JS, Liu Y, Paukner S. In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China. Antimicrob Agents Chemother. 2017;61(2):e02008-e2016. https:\/\/doi.org\/10.1128\/AAC.02008-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"378_CR41","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/jac\/dks001","volume":"67","author":"HS Sader","year":"2012","unstructured":"Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother. 2012;67(5):1170\u20135. https:\/\/doi.org\/10.1093\/jac\/dks001.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"378_CR42","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1128\/AAC.00358-13","volume":"57","author":"S Paukner","year":"2013","unstructured":"Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013;57(9):4489\u20134495. https:\/\/doi.org\/10.1128\/AAC.00358-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"378_CR43","doi-asserted-by":"publisher","unstructured":"File Jr TM, Goldberg L, Das A, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP\u00a01) trial. Clin Infect Dis. 2019;69(11):1856\u20131867. https:\/\/doi.org\/10.1128\/AAC.00358-13.","DOI":"10.1128\/AAC.00358-13"},{"key":"378_CR44","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.2019.15468","volume":"322","author":"E Alexander","year":"2019","unstructured":"Alexander E, Goldberg L, Das AF, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP\u00a02 randomized clinical trial. JAMA. 2019;322:1661\u201371. https:\/\/doi.org\/10.1001\/jama.2019.15468.","journal-title":"JAMA"},{"issue":"5","key":"378_CR45","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1128\/AAC.02106-12","volume":"57","author":"WT Prince","year":"2013","unstructured":"Prince WT, Ivezic-Schoenfeld Z, Lell C, et al. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrobial Agents Chemother. 2013;57(5):2087\u201394.","journal-title":"Antimicrobial Agents Chemother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00378-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40121-020-00378-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00378-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T06:52:50Z","timestamp":1615531970000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-020-00378-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1007\/s40121-020-00378-3","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}